The three C study (canakinumab in COVID-19 cardiac injury) was a double-blind randomized proof-of-concept trial that enrolled 45 patients with moderate COVID-19, myocardial injury (defined by a troponin greater than 99% upper reference range without signs or symptoms of acute myocardial ischemia), and CRP >50 mg/L.96 This evidence concerns the gene CRP and COVID-19.